Assessment of durable responses after brexucabtagene autoleucel (brexu-cel) in relapsed/refractory mantle cell lymphoma (R/R MCL)

被引：0
|
作者：
Pindoria, Lohit
Munoz, Javier [2 ]
Reagan, Patrick [3 ]
Goy, Andre [4 ]
Miklos, David [5 ]
Zheng, Dan [1 ]
Fang, Xiang [1 ]
Shen, Rhine [1 ]
Siddiqi, Rubina [1 ]
Kloos, Ioana [1 ]
Kersten, Marie Jose [6 ]
Wang, Michael [7 ]
机构：
[1] Kite, Santa Monica, CA USA
[2] Banner MD Anderson Canc Ctr, Gilbert, AZ USA
[3] Univ Rochester, Sch Med, Rochester, NY USA
[4] John Theurer Canc Ctr, Hackensack, NJ USA
[5] Stanford Univ, Sch Med, Stanford, CA USA
[6] Univ Amsterdam, Amsterdam UMC, HOVON LLPC, Amsterdam, Netherlands
[7] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2023年 / 201卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
BSH23-PO88
引用
收藏
页码：113 / 114
页数：2
相关论文
共 50 条
  • [1] Real-world outcomes of brexucabtagene autoleucel (brexu-cel) for relapsed or refractory (R/R) mantle cell lymphoma (MCL): A CIBMTR subgroup analysis by prior treatment.
    Kambhampati, Swetha
    Ahmed, Nausheen
    Hamadani, Mehdi
    Grover, Natalie Sophia
    Shadman, Mazyar
    Locke, Frederick L.
    Gerson, James M.
    Frank, Matthew Joshua
    Budde, Lihua Elizabeth
    Wang, Michael
    Hu, Zhen-Huan
    Nunes, Ana
    Dalton, David
    Kloos, Ioana
    Lee, Daniel
    Xu, Hairong
    Pasquini, Marcelo C.
    Herrera, Alex Francisco
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Real-World Outcomes of Brexucabtagene Autoleucel ( Brexu-cel) for Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL): A CIBMTR Subgroup Analysis of High-Risk Characteristics
    Kambhampati, Swetha
    Ahmed, Nausheen
    Hamadani, Mehdi
    Kim, Soyoung
    Hemmer, Michael T.
    Grover, Natalie S.
    Shadman, Mazyar
    Beitinjaneh, Amer
    Budde, L. Elizabeth
    Gerson, James
    Jacobson, Caron A.
    Locke, Frederick L.
    Nasta, Dwivedy S.
    Wang, Michael L.
    Weng, Wen-Kai
    Yan, Jiali
    Nunes, Ana
    Dalton, David
    Wu, James J.
    Abdeldaim, Amina
    Hu, Zhen-Huan
    Pasquini, Marcelo
    Herrera, Alex F.
    BLOOD, 2023, 142
  • [3] Outcomes of Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 and ZUMA-18, an Expanded Access Study
    Goy, Andre
    Jacobson, Caron A.
    Flinn, Ian W.
    Hill, Brian T.
    Weng, Wen-Kai
    Mountjoy, Luke
    Olalekan, Oluwole
    Zheng, Dan
    Nunes, Ana
    Zhang, Wangshu
    Shen, Rhine R.
    Kloos, Ioana
    Wang, Michael L.
    BLOOD, 2023, 142
  • [4] Assessment of Early Intervention Strategies for Management of Cytokine Release Syndrome and Neurologic Events after Brexucabtagene Autoleucel ( Brexu-Cel) Treatment in Patients with Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL) in ZUMA-2
    Oluwole, Olalekan O.
    Reagan, Patrick M.
    Miklos, David B.
    Locke, Frederick L.
    Goy, Andre
    Jacobson, Caron A.
    Munoz, Javier L.
    Forcade, Edouard
    Topp, Max S.
    Zheng, Dan
    Nunes, Ana
    Zhang, Wangshu
    Shen, Rhine R.
    Kloos, Ioana
    Kersten, Marie Jose
    Wang, Michael L.
    BLOOD, 2023, 142
  • [5] Brexucabtagene autoleucel in relapsed/refractory mantle cell lymphoma (R/R MCL) in ZUMA-2: Durable responder analysis
    Munoz, Javier
    Reagan, Patrick M.
    Goy, Andre
    Miklos, David B.
    Zheng, Dan
    Fang, Xiang
    Shen, Rhine R.
    Siddiqi, Rubina
    Kloos, Ioana
    Kersten, Marie Jose
    Wang, Michael
    ANNALS OF ONCOLOGY, 2023, 34 : S1380 - S1380
  • [6] Outpatient Administration of Brexucabtagene Autoleucel (brexu-cel) for Acute Lymphoblastic Leukemia (ALL) and Mantle Cell Lymphoma (MCL) Is Safe and Feasible
    Othman, Tamer
    Baird, John H.
    Wang, Yan
    Pak, Stacy
    Aldoss, Ibrahim
    Cai, Ji-Lian
    Danilov, Alexey
    Phillips, Tycel J.
    Agrawal, Uaibhav
    Sandhu, Karamjeet S.
    Mei, Matthew
    Koller, Paul B.
    Palmer, Joycelynne Michelle
    Forman, Stephen J.
    Budde, Lihua E.
    Aribi, Ahmed
    BLOOD, 2024, 144 : 2278 - 2279
  • [7] COST-EFFECTIVENESS OF BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL, CAR-T) FOR THE TREATMENT OF RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA IN GREECE
    Loupas, M. A.
    Theodoratou, D.
    Kourlaba, G.
    VALUE IN HEALTH, 2022, 25 (12) : S112 - S112
  • [8] Assessment of Durable Responses after Brexucabtagene Autoleucel (KTE-X19) in the ZUMA-2 Study in Relapsed/ Refractory Mantle Cell Lymphoma (R/R MCL)
    Munoz, Javier
    Reagan, Patrick M.
    Goy, Andre H.
    Miklos, David B.
    Zheng, Dan
    Fang, Xiang
    Shen, Rhine R.
    Siddiqi, Rubina
    Kloos, Ioana
    Kersten, Marie Jose
    Wang, Michael
    BLOOD, 2022, 140 : 9320 - 9322
  • [9] Matching-Adjusted Indirect Comparison (MAIC) of Brexucabtagene Autoleucel (Brexu-cel) and Pirtobrutinib in Patients with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (cBTKi)
    Chen, Jenny M. H.
    Zhang, Ina
    Wu, James J.
    Wade, Sally W.
    Nunes, Ana
    Peng, Weimin
    Snider, Julia T.
    Maciel, Dylan
    Chan, Keith
    Keeping, Sam
    Shah, Bijal D.
    BLOOD, 2023, 142
  • [10] Primary Analysis of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel (Brexu-Cel) in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Who Were Naive to Bruton Tyrosine Kinase Inhibitors (BTKi)
    van Meerten, Tom
    Kersten, M. J.
    Lacoboni, Gloria
    Hess, Georg
    Mutsaers, Pim
    Garcia-Sancho, Alejandro Martin
    Goy, Andre
    Gine, Eva
    Hill, Brian T.
    Weng, Wen-Kai
    Dreyling, Martin
    Reagan, Patrick M.
    Patel, Krish
    Galal, Ahmed
    Herbaux, Charles
    Sanderson, Robin
    Zheng, Dan
    Kanska, Justyna
    Zhang, Wangshu
    Khalid, Rita Damico
    Kloos, Loana
    Wang, Michael
    BLOOD, 2024, 144 : 748 - 750
12345